Veritas Pharma Inc.

A discovery & development company focused on scientifically finding new medicinal cannabis cultivars for specific disease conditions

Learn More

Our Research Aims

To chemically profile different marijuana cultivars

To pharmacologically profile those same cultivars in the search for disease specific strains

To perform clinical trials to establish the clinical utility of a cultivar

Investors

Veritas Pharma is listed on the Canadian Securities Exchange: VRT;  the OTC: VRTHF; and the Frankfurt exchange: 2VP. Read more here about investing in Veritas Pharma Inc.

CSE:VRT

OTC:VRTHF

FRT: 2VP

First Order of Cannabis Strains Placed With Whistler Medical Marijuana Corporation

May 10, 2016, Vancouver, B.C. – Veritas Pharma Inc. (“VRT” or the “Company”) (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) is pleased to announce that the first order of two popular cannabis strains has been placed with Whistler Medical Marijuana Corporation. Veritas...
Read More

Health Canada Approval Received

May 3, 2016, Vancouver, B.C. – Cannevert Therapeutics Ltd., the research partner of Veritas Pharma Inc. (“VRT” or the “Company”) (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) has obtained an exemption from Health Canada to legally perform cannabis research. “We’re...
Read More

Veritas Pharma Inc. Hires Local Intellectual Property Law Firm to Protect its New Cannabis Cultivars for Specific Disease Conditions

April 28, 2016, Vancouver, B.C. – Veritas Pharma Inc. (“VRT” or the “Company”) (CSE: VRT; OTC: VRTHF; and Frankfurt:2VP) is pleased to announce that it has hired local intellectual property law firm Oyen Wiggs Green & Mutala LLP to oversee the patenting of its new...
Read More